This is a multi-center, prospective, controlled study. MS patients (1° group: 30 patients in relapse; 2° group: 30 patients in remission) and age/sex-matched healthy controls (3° group: 30 subjects) will be enrolled in the study. Patients' disability level will be evaluated by EDSS and MSFC. Patients and controls will be tested for either coagulation/complement (C3, C4, C4a, C9, fibrinogen, factor VIII and X, D-dimer, protein C, protein S, antithrombin, factor II, aPTT, von-Willebrand factor), soluble markers of endothelial damage (thrombomodulin, Endothelial Protein C Receptor), antiphospholipid antibodies, lupus anticoagulant, complete blood count, viral serological assays or microRNA microarray. Patients will undergo dynamic susceptibility contrast-enhanced MRI using a 3.0-T scanner to evaluate CBF, CBV, MTT, lesion number and volume.
Study Type
OBSERVATIONAL
Enrollment
80
DSC perfusion technique at 3.0-T MRI only in MS patients
Icahn School of Medicine at Mount Sinai
New York, New York, United States
IRCCS Regina Elena National Cancer Institute
Rome, Italy
University of Rome Sapienza
Rome, Italy
plasma concentration of coagulation factor
Factor VIII (%)
Time frame: through study completion, an average of 1 year
plasma concentration of coagulation factor
Factor X (%)
Time frame: through study completion, an average of 1 year
plasma concentration of coagulation factor
D-dimer (ng/ml)
Time frame: through study completion, an average of 1 year
plasma concentration of coagulation factor
Protein C (%)
Time frame: through study completion, an average of 1 year
plasma concentration of coagulation factor
Protein S (%)
Time frame: through study completion, an average of 1 year
plasma concentration of coagulation factor
Fibrinogen (mg/dl)
Time frame: through study completion, an average of 1 year
plasma concentration of coagulation factor
complement (mg/dl)
Time frame: through study completion, an average of 1 year
Brain MRI hemodynamic changes at DSC 3.0-T MRI
cerebral blood flow
Time frame: through study completion, an average of 1 year
Brain MRI hemodynamic changes at DSC 3.0-T MRI
cerebral blood volume
Time frame: through study completion, an average of 1 year
Brain MRI hemodynamic changes at DSC 3.0-T MRI
mean transit time
Time frame: through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.